Poster Hall

Zoster vaccine immunogenicity with JAKi treatment

Save

Sponsored by AbbVie Medical Affairs

Dec 02, 2024

More Virtual Posters

A US Patient Perspective on the Diagnosis and Burden of AxSpA

Sponsored by AbbVie Medical Affairs

Safety of a JAKi Across 15,000 Patient-Years of Data

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies

Sponsored by AbbVie Medical Affairs

Safety and Efficacy of a JAKi in Patients With Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 204 From the SELECT-CHOICE Study

Non-Pharmacologic Interventions for Rheumatoid Arthritis

Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients With Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension

Sponsored by Sanofi

Sustained Remission From Weeks 16 to 52 and Weeks 24 to 52 in Patients Treated With Sarilumab: Post-hoc Analysis of SAPHYR Trial in Patients With Polymyalgia Rheumatica

Sponsored by CorEvitas, LLC. And UCB Pharma

Durability of Response Among Psoriatic Arthritis (PsA) Patients Using Biological/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs) in the CorEvitas PsA/Spondyloarthritis Registry

Sponsored by AbbVie Medical Affairs

Safety Profile of a JAKi in Patients with Rheumatoid Arthritis With up to 6.5 Years of Exposure

Sponsored by AbbVie Medical Affairs

Safety and Efficacy of a JAKi in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years From the SELECT-BEYOND Study

Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus

Bimekizumab Maintains Improvements in Efficacy Endpoints and has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

Sponsored by Sanofi

Glucocorticoid (GC)-free resolution of polymyalgia rheumatica (PMR) signs and symptoms in patients treated with sarilumab with history of flare: analysis from SAPHYR

Sponsored by Sanofi

Patient reported outcomes from a Randomized Controlled Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica

Sponsored by Sanofi

Topics

Poster Hall

Zoster vaccine immunogenicity with JAKi treatment

Save

More Virtual Posters

A US Patient Perspective on the Diagnosis and Burden of AxSpA

Safety of a JAKi Across 15,000 Patient-Years of Data

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies

Safety and Efficacy of a JAKi in Patients With Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 204 From the SELECT-CHOICE Study

Non-Pharmacologic Interventions for Rheumatoid Arthritis

Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients With Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension

Sustained Remission From Weeks 16 to 52 and Weeks 24 to 52 in Patients Treated With Sarilumab: Post-hoc Analysis of SAPHYR Trial in Patients With Polymyalgia Rheumatica

Durability of Response Among Psoriatic Arthritis (PsA) Patients Using Biological/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs) in the CorEvitas PsA/Spondyloarthritis Registry

Safety Profile of a JAKi in Patients with Rheumatoid Arthritis With up to 6.5 Years of Exposure

Safety and Efficacy of a JAKi in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years From the SELECT-BEYOND Study

Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus

Bimekizumab Maintains Improvements in Efficacy Endpoints and has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

Glucocorticoid (GC)-free resolution of polymyalgia rheumatica (PMR) signs and symptoms in patients treated with sarilumab with history of flare: analysis from SAPHYR

Patient reported outcomes from a Randomized Controlled Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica

Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)

Do you get our email newsletter?